Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and immunogenicity of the ChAdOx1-VZV vaccine in healthy adults aged 50-65 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Herpes Zoster

Drugs mentioned

• ChAdOx1-VZV (ChAdOx1-VZV)

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Herpes Zoster | Phase 1 | Status: COMPLETED